Application of stigmastane mixture to promotion of collagen generation
By using a mixture of stigmasterane-22-ene-3,6-dione and 5α-stigmasterane-3,6-dione, it promotes the production of skin collagen, solves the problem of skin aging, and improves skin tightness and anti-aging effects.
Patent Information
- Application Number
- CN202410970869.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-08
AI Technical Summary
With the increase of age and the destruction of external environment such as ultraviolet rays, collagen in the human body continues to lose, resulting in skin sagging and wrinkles. The existing technology is difficult to effectively promote collagen production to resist skin aging.
Use a mixture of stigmasterane-22-ene-3,6-dione and 5α-stigmasterane-3,6-dione as a functional additive to prepare skin topical agents, medicines and health foods to promote type I collagen Protein is produced at a concentration of at least 0.05 mg/L and a content of 0.000005-10% by weight.
It significantly promotes the production of collagen in fibroblasts, improves skin sagging and wrinkle problems, resists skin aging, and is effectively used in low toxic concentrations.
Smart Images

Figure BDA0004953367540000021 
Figure BDA0004953367540000022 
Figure BDA0004953367540000121
Abstract
Description
Technical Field
[0001] The invention relates to the field of natural drug chemistry, and in particular to the use of a stigmasterane mixture in promoting collagen production, and the use of the stigmasterane mixture in preparing a skin external preparation, a medicine and a health food having the effect of promoting collagen production. Background Art
[0002] Our skin is composed of three parts: the epidermis, dermis and subcutaneous tissue. Among them, the epidermis mainly plays a protective role, the subcutaneous tissue is composed of a large number of fat cells and connective tissue, with a large number of nerves and blood vessels, and mainly plays a role in providing nutrition, and the dermis is mainly composed of a large number of elastic fibers, hyaluronic acid and fibroblasts. Fibroblasts (abbreviated as Fb), also known as fibroblasts, are the main cell components of loose connective tissue, which are differentiated from mesenchymal cells in the embryonic period. Fibroblasts are large, with clear outlines, and are mostly protruding spindle-shaped or star-shaped flat structures. Fibroblasts account for more than 95% of the cells in the dermis, and their normal differentiation and proliferation maintain the normal structure and physiological function of the skin. Fb has a strong protein synthesis ability, and can synthesize and secrete a large number of matrix components such as elastin, collagen, glycosaminoglycans and glycoproteins, thereby generating elastic fibers, collagen fibers and reticular fibers, and secreting a variety of cell repair factors, which give the skin a strong renewal and self-repair ability, thereby increasing the thickness and density of the dermis of the skin, which has the potential to stretch wrinkles and restore skin elasticity and luster.
[0003] Collagen is a biopolymer and the main component of connective tissue. It is also the most abundant and widely distributed functional protein in mammals. Collagen can be divided into fibrous collagen and non-fibrous collagen. Fibrous collagen is mainly type I, type III and type V. Among them, Collagen I is the most abundant, which is related to the skin's resistance to stretching and has a strong tensile strength. Elastin is the main component of elastic fibers. It is particularly abundant in the connective tissue of the skin and exists at the same time as collagen fibers, giving the tissue elasticity and tension resistance. It allows the skin to stretch and fold, and is responsible for maintaining and supporting the elasticity of the skin.
[0004] The content of collagen is the decisive factor in the degree of skin aging. Collagen accounts for 72% of the skin, and the content of collagen in the dermis is as high as 80%. Collagen is secreted by fibroblasts and exists in the extracellular matrix, playing a supporting role in the entire skin. Collagen has a three-dimensional spiral structure, which can lock the moisture deep in the skin, making the skin moisturized, smooth and shiny. Therefore, collagen is also known as the "soft gold in the skin". However, once collagen breaks and loses, the dermis will collapse, the skin will become loose, droopy, and wrinkles will appear. As people age and are damaged by external environments such as ultraviolet rays, the collagen in the human body is constantly lost. In order to maintain skin elasticity, slow down or even resist skin aging, it is necessary to increase the collagen content in human skin.
[0005] The specific stigmasterane mixture is a mixture of stigmasterane-22-ene-3,6-dione and 5α-stigmasterane-3,6-dione in a ratio of about 1:1 (weight ratio), which can be separated and purified from plants such as chamomile and Ailanthus.
[0006] English name: Stigmasta-22-ene-3,6-dione, CAS number: 88661-99-8, molecular weight: 426.7, molecular formula: C 29 H 46 O2. The structural formula of stigmasterane-22-ene-3,6-dione is:
[0007]
[0008] 5α-stigmastan-3,6-dione English name: 5α-stigmasta-3,6-dione, CAS number: 22149-69-5, molecular weight: 428.7, molecular formula: C 29 H 48 O2. The structural formula of 5α-stigmasterane-3,6-dione is:
[0009]
[0010] The molecular weight of the stigmasterane mixture is the average molecular weight of the two: 427.7.
[0011] Wang Yuan analyzed the compound components in Croton tiglium and isolated 29 compounds from the 95% ethanol extract of its stem, including stigmasterane-22-ene-3,6-dione; Feng Yalong isolated and identified 33 compounds from the ethyl acetate part of the 80% methanol extract of Plantago, including 5α-stigmasterane-3,6-dione; Chang Xuejian isolated and identified 24 monomer compounds from the active fraction of Scutellaria serrata, including 5α-stigmasterane-3,6-dione. Tu Pengfei extracted and purified litchi kernels using 70% ethanol and finally identified 13 compounds, including stigmasterane-22-ene-3,6-dione and 5α-stigmasterane-3,6-dione. Although there are many papers reporting on the separation and purification of stigmasterane mixtures or their components, none of them have studied the biological activity of stigmasterane mixtures or their components, especially the skin care effects.
[0012] The present invention unexpectedly discovered that the stigmasterane mixture has an excellent effect of promoting collagen production and can be used as an effective additive in skin external preparations, medicines and health foods. Summary of the invention
[0013] The invention provides application of a stigmasterane mixture in promoting collagen production.
[0014] In a preferred embodiment, the collagen is type I collagen.
[0015] In a preferred embodiment, the stigmasterane mixture is used at a concentration of at least 0.05 mg / L, more preferably at least 0.1 mg / L.
[0016] The invention also relates to the application of the stigmasterane mixture in the preparation of skin external preparations, medicines and health foods having the function of promoting collagen production.
[0017] In a preferred embodiment, the content of the stigmasterane mixture in the external skin preparation, medicine and health food is 0.000005-10% by weight, more preferably 0.00001-5% by weight.
[0018] In a preferred embodiment, the skin external preparation is selected from: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Cell morphology images showing solvent control toxicity to fibroblasts are shown.
[0021] Figure 2 The cell morphology diagram shows the toxicity of 0.53 mg / L stigmasterane mixture to fibroblasts.
[0022] Figure 3 The cell morphology of the toxicity of 0.27 mg / L stigmasterane mixture to fibroblasts is shown.
[0023] Figure 4 The cell morphology diagram shows the toxicity of 0.13 mg / L stigmasterane mixture to fibroblasts.
[0024] Figure 5 The cell morphology of the toxicity of 0.07 mg / L stigmasterane mixture to fibroblasts is shown.
[0025] Figure 6 The cell morphology diagram shows the toxicity of 0.03 mg / L stigmasterane mixture to fibroblasts. DETAILED DESCRIPTION
[0026] The present invention relates to the effect of a stigmasterane mixture on promoting collagen production. It is unexpectedly discovered for the first time that a stigmasterane mixture can be used as an effective additive for preparing skin topical preparations, medicines and health foods to help achieve the effects of maintaining skin firmness, improving skin sagging and / or wrinkles, resisting skin aging and the like.
[0027] In order to provide a more concise description, some quantitative expressions given herein are not modified by the term "about". It should be understood that, whether or not the term "about" is explicitly used, each quantity given herein is intended to refer to the actual given value, and is also intended to refer to the approximate values of these given values that can be reasonably inferred by ordinary technicians in the field, including the approximate values of these given values caused by experimental and / or measurement conditions.
[0028] To provide a more concise description, some quantitative expressions herein are described as a range of about X amount to about Y amount. It should be understood that when describing a range, the range is not limited to the upper and lower limits described, but should include the entire range of about X amount to about Y amount or any amount therebetween.
[0029] The stigmasterane mixtures described herein may optionally be in finished packaging form. In one embodiment, the packaging is a container such as a plastic, metal or glass tube or jar containing the stigmasterane mixture. The product may additionally have packaging such as a plastic or cardboard box for storing the container. In one embodiment, the product comprises the stigmasterane mixture and has instructions for directing the user to apply the stigmasterane mixture to the skin to treat signs of skin aging as discussed below. Such instructions may be printed on the container, a label insert, or any other packaging.
[0030] As used herein, "topical application" means applying or spreading directly onto the external skin, scalp, or hair, for example, using the hands or an application device such as a wipe, roller, or spray.
[0031] As used herein, "cosmetically acceptable" means that the ingredients described by the term are suitable for use in contact with tissue (eg, skin or hair) without undue toxicity, incompatibility, instability, irritation, allergic response, or the like.
[0032] The present invention has found that the stigmasterane mixture is suitable for treating signs of skin aging. As used herein, "signs of skin aging" include the presence of fine lines and wrinkles, loss of elasticity, uneven skin tone, and scarring. In a particularly preferred embodiment, the signs of aging are the presence of fine lines and wrinkles and / or loss of elasticity.
[0033] As used herein, "treating the signs of skin aging" means alleviating, reducing, preventing, ameliorating or eliminating the presence or signs of skin aging as described above.
[0034] As used herein, "wrinkles" include fine lines, micro wrinkles or macro wrinkles. Examples of wrinkles include, but are not limited to, fine lines around the eyes (e.g., "crow's feet"), forehead and cheek wrinkles, frown lines, and smile lines around the mouth.
[0035] As used herein, "loss of elasticity" includes loss of elasticity or structural integrity of skin or tissue, including but not limited to sagging, loose and loose tissue. Loss of elasticity or tissue structural integrity can be caused by a variety of factors, including but not limited to disease, aging, hormonal changes, mechanical trauma, environmental damage, or as a result of applying products such as cosmetics or drugs to the tissue.
[0036] As used herein, "uneven skin tone" refers to a skin condition associated with diffuse or mottled pigmentation that can be classified as hyperpigmentation, such as post-inflammatory hyperpigmentation.
[0037] As used herein, "scarring" means a skin condition associated with redness or erythema.
[0038] As used herein, "cosmetic" refers to cosmetic substances or preparations that maintain, restore, impart, stimulate, or enhance the physical appearance or seem to increase beauty or youthfulness, especially as it relates to the appearance of tissue or skin.
[0039] As used herein, "cosmetically effective amount" means an amount of a physiologically active compound or composition sufficient to treat one or more signs of skin aging, but low enough to avoid serious side effects. The cosmetically effective amount of a compound or composition will vary depending on the specific condition being treated, the age and physical condition of the end user, the severity of the condition being treated / prevented, the duration of the treatment, the nature of other treatments, the specific compound or product / composition employed, the specific cosmetically acceptable carrier utilized, and the like.
[0040] Stigmasterane mixture
[0041] The present invention is based on the following unexpected discovery: the stigmasterane mixture has the effect of promoting fibroblasts to produce collagen. Therefore, the stigmasterane mixture can be added to skin care products as an effective ingredient to help improve skin sagging, wrinkle problems, etc. The purpose of the present invention is to provide the effect of the stigmasterane mixture on promoting collagen production and its application in cosmetics.
[0042] In the application of promoting fibroblasts to produce collagen, the concentration of the stigmasterane mixture is at least 0.05 mg / L, more preferably at least 0.1 mg / L.
[0043] In some embodiments, the stigmasterane mixture is used at a concentration of preferably less than 0.2 mg / L, more preferably less than 0.13 mg / L.
[0044] In some embodiments, the stigmasterane mixture is used at a concentration of 0.05-0.5 mg / L, preferably 0.1-0.2 mg / L, and more preferably 0.1-0.13 mg / L.
[0045] Skin topical products
[0046] In some embodiments, the stigmasterane mixture can be used for the preparation of a skin topical preparation. The skin topical preparation is preferably a cosmetic composition, including but not limited to products in the form of cream, lotion, gel, toner, essence, mask, eye cream, aerosol (cleansing foam), spray, shower gel and facial cleanser.
[0047] The content of the stigmasterane mixture in the external preparation for skin may be: In some embodiments, W / W.
[0048] The skin external preparation is a general concept for all ingredients usually used on the outside of the skin, for example, it can be a cosmetic composition. The cosmetic composition can be a basic cosmetic, a facial makeup cosmetic, a body cosmetic, a hair care cosmetic, etc., and there is no special restriction on its dosage form, which can be reasonably selected according to different purposes. The cosmetic composition also contains different media or matrix excipients allowed by the cosmetics level according to different dosage forms and purposes.
[0049] The skin topical preparation comprising the stigmasterane mixture can be topically applied to human skin and / or hair. The skin topical preparation can also include a cosmetically acceptable topical carrier, which can be about 50% by weight to about 99.99% by weight of the skin topical preparation (such as about 80% by weight to about 99% by weight of the skin topical preparation). In a preferred embodiment of the present invention, the cosmetically acceptable topical carrier comprises water. The cosmetically acceptable topical carrier may include one or more selected from wetting agents, emollients, grease, wetting agents and similar substances. In one embodiment, the cosmetically acceptable topical carrier comprises a substrate such as a nonwoven fabric or a membrane material.
[0050] Skin topical agents can be prepared into a variety of product types, including but not limited to lotions, creams, gels, sticks, sprays, ointments, cleansing liquid lotions and solid soaps, shampoos and hair conditioners, hair fixatives, pastes, foams, powders, mousses, shaving creams, wipes, patches, hydrogels, film-forming products, facial masks and skin films, films and cosmetics such as foundation and mascara. These product types can contain several types of cosmetically acceptable topical carriers, including but not limited to solutions, suspensions, emulsions (e.g., microemulsions and nanoemulsions), gels, solids and liposomes.
[0051] The topical skin preparation containing the stigmasterane mixture can be formulated as a solution. The solution generally contains an aqueous solvent or an organic solvent (e.g., about 50% to about 99.99% or about 90% to about 99% of a cosmetically acceptable aqueous solvent or organic solvent). Examples of suitable organic solvents include propylene glycol, polyethylene glycol, polypropylene glycol, glycerol, 1,2,4-butanetriol, sorbitan esters, 1,2,6-hexanetriol, ethanol, and mixtures thereof.
[0052] Skin topical preparations can be formulated into solutions containing emollients. Such skin topical preparations preferably contain from about 2% to about 50% of one or more emollients. As used herein, "emollient" refers to a substance used to prevent or alleviate dryness, for example, by preventing the loss of skin moisture through the skin. Examples of emollients include, but are not limited to, vegetable oils, mineral oils, aliphatic esters, etc.
[0053] Lotions can be prepared from such solutions.Lotions typically contain from about 1% to about 20% (e.g., from about 5% to about 10%) of one or more emollients and from about 50% to about 90% (e.g., from about 60% to about 80%) water.
[0054] Another type of product that can be formulated from a solution is a cream. Creams typically contain from about 5% to about 50% (e.g., from about 10% to about 20%) of one or more emollients and from about 45% to about 85% (e.g., from about 50% to about 75%) water.
[0055] Although it is preferred that the topical skin preparation containing the stigmasterane mixture contains water, the topical skin preparation may alternatively be anhydrous or an ointment containing no water but organic and / or silicone solvents, oils, lipids and waxes. The ointment may contain a simple base of animal or vegetable oils or semisolid hydrocarbons. The ointment may contain from about 2% to about 10% of one or more emollients and from about 0.1% to about 2% of one or more thickeners.
[0056] The topical agent for skin application can be formulated as an emulsion. If the topical carrier is an emulsion, about 1% to about 10% (e.g., about 2% to about 5%) of the topical carrier contains one or more emulsifiers. The emulsifier can be nonionic, anionic or cationic. Examples of suitable emulsifiers include those commonly identified as suitable emulsifiers in the field of personal care and cosmetic formulations.
[0057] Lotions and creams can be formulated as emulsions. Typically such lotions contain 0.5% to about 5% of one or more emulsifiers. Such creams typically contain about 1% to about 20% (e.g., about 5% to about 10%) of one or more emollients; about 20% to about 80% (e.g., 30% to about 70%) of water; and about 1% to about 10% (e.g., about 2% to about 5%) of one or more emulsifiers.
[0058] Oil-in-water and water-in-oil type single emulsion skin care preparations, such as lotions and creams, are well known in the cosmetics field and can be used in the present invention. Multiphase emulsion skin external preparations (such as water-in-oil-in-water type and oil-in-water-in-oil type) can also be used in the present invention. Generally, such single-phase emulsions or multiphase emulsions contain water, emollients and emulsifiers as their basic ingredients.
[0059] Skin topical preparations containing the stigmasterane mixture can also be formulated into gels (e.g., aqueous gels, alcoholic gels, alcohol / water gels, or oily gels using suitable gelling agents). Suitable gelling agents for aqueous gels and / or alcoholic gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethyl cellulose and hydroxypropyl cellulose). Suitable gelling agents for oils (e.g., mineral oils) include, but are not limited to, hydrogenated butylene / ethylene / styrene copolymers and hydrogenated ethylene / propylene / styrene copolymers. Such gels typically contain between about 0.1% and 5% by weight of such gelling agents.
[0060] The topical skin preparation comprising the stigmasterane mixture may also be formulated as a solid preparation (eg, a wax-based stick, a bar soap, a powder, or a wipe containing a powder).
[0061] In addition to the above-mentioned components, the external preparation for skin which can be used in the present invention may contain various other oil-soluble substances and / or water-soluble substances at levels conventionally established in its technical field for use in external preparations for skin for use on skin and hair.
[0062] The skin external preparation of the present invention may contain additional components commonly found in skin care compositions, such as emollients, skin regulators, emulsifiers, preservatives, antioxidants, fragrances, chelating agents, etc., as long as they are physically and chemically compatible with other components in the skin external preparation and do not affect the effects of the stigmasterane mixture of the present invention.
[0063] In some embodiments of the skin topical preparation of the present invention, one or more preservatives may be used. Suitable preservatives include p-hydroxyacetophenone, C1-C4 alkyl parahydroxybenzoate and phenoxyethanol. Based on the total weight of the composition, the amount of the preservative is about 0.5 to about 2 weight %, preferably about 0.5 to 1 weight %.
[0064] In one example of the skin external preparation of the present invention, one or more antioxidants can be used. Suitable antioxidants include butylated hydroxytoluene (BHT), ascorbyl palmitate (BHA), butylated hydroxyanisole, phenyl-α-naphthylamine, hydroquinone, propyl gallate, nordihydroguaiaretic acid, vitamin E or vitamin E derivatives, vitamin C and its derivatives, calcium pantothenate, green tea extract and mixed polyphenols, and mixtures of the above-mentioned substances. The antioxidant used is about 0.02 to 0.5 weight % of the total weight of the composition, and more preferably from about 0.002 to 0.1 weight % of the amount used.
[0065] In one example of the skin external preparation of the present invention, one or more emollients can be used to act as lubricants through their ability to remain on the skin surface or in the stratum corneum to reduce flaking and improve the appearance of the skin. Typical emollients include fatty esters, fatty alcohols, mineral oils, polyether silicone copolymers, and the like. Examples of suitable emollients include, but are not limited to, polypropylene glycol ("PPG")-15 stearyl ether, PPG-10 cetyl ether, Steareth-10, Oleth-8, PPG-4 lauryl ether, vitamin E acetate, lanolin, cetyl alcohol, cetearyl ethylhexanoate, cetearyl alcohol, glyceryl stearate, hydroxystearate octyl, dimethyl polysiloxane, and combinations thereof. Cetyl alcohol, cetearyl ethylhexanoate, cetearyl alcohol, glyceryl stearate, and combinations thereof are preferred. When used, the emollient is used in an amount ranging from about 0.1 to about 30% by weight, preferably about 1 to about 30% by weight, based on the total weight of the composition.
[0066] In one example of the skin external preparation of the present invention, one or more moisturizers can be used. Moisturizers are also called humectants, which help to improve the effect of emollients, reduce flaking, remove the scales of the composition and improve the touch of the skin. Polyols can be used as moisturizers, including but not limited to glycerol, polyalkylene glycols, alkylene polyols and derivatives thereof, including butylene glycol, propylene glycol, dipropylene glycol, polyglycerol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-dibutylene glycol, 1,2,6-hexanetriol, ethoxylated glycerol, propoxylated glycerol, and combinations thereof. When used, the amount of moisturizer is about 0.1 to about 20% by weight, preferably about 1 to about 15% by weight, based on the total weight of the composition.
[0067] In an example of the skin external preparation of the present invention, one or more emulsifiers can be used. Emulsifiers can be used within the scope of effective stabilizing amount. Preferably, based on the total weight of the composition, the emulsifier is used in an amount of about 1.0 to about 10.0 weight %, more preferably about 3.0 to about 6.0 weight %. Any emulsifier compatible with the components in the composition can be used. Suitable emulsifiers include stearic acid, cetyl alcohol, glyceryl stearate, lecithin, stearyl alcohol, Steareth-2, Steareth-20, acrylic acid (ester) class / C10-30 alkyl alcohol acrylate cross-linked polymer, and combinations thereof.
[0068] In one example of the skin external preparation of the present invention, one or more pH regulators can be used. The pH regulator useful in the skin external preparation of the present invention includes tromethamine. When used, the amount of the pH regulator based on the total weight of the composition is about 0.1 to about 2 weight %, preferably about 0.1 to about 1 weight %.
[0069] In a specific embodiment of the present invention, the skin topical agent comprises acrylates / C10-30 alkyl acrylate crosspolymer, glycerin, p-hydroxyacetophenone, glyceryl stearate and lecithin, cetearyl alcohol, cetearyl ethylhexanoate, tromethamine or a combination thereof.
[0070] Additional cosmetic active agents
[0071] In some embodiments, the topical skin preparation may also include additional cosmetic active agents. As used herein, "cosmetic active agents" are compounds (such as synthetic compounds or compounds isolated from natural sources or natural extracts) that have cosmetic or therapeutic effects on skin or hair, including but not limited to anti-acne agents, oil control agents, antimicrobial agents, anti-inflammatory agents, antifungal agents, antiparasitic agents, topical analgesics, sunscreens, photoprotectants, antioxidants, keratolytic agents, surfactants, moisturizers, nutrients, vitamins, energy enhancers, antiperspirants, astringents, deodorants, curing agents, anti-hard cuticle agents, and agents for hair and / or skin conditioning.
[0072] In one embodiment, these cosmetic actives are selected from (but not limited to): hydroxy acids, benzoyl peroxide, D-panthenol, octyl methoxycinnamate, titanium dioxide, octyl salicylate, homosalate, avobenzone, carotenoids, free radical scavengers, spin traps, amines, retinoids such as retinol and retinyl palmitate, ceramides, polyunsaturated fatty acids, essential fatty acids, enzymes, enzyme inhibitors, minerals, hormones such as estrogen, steroids such as hydrocortisone, 2-dimethylaminoethanol, copper salts such as copper chloride, copper-containing peptides such as Cu:Gly-His-Lys, coenzyme Q10, peptides, amino acids such as proline, vitamins, lactobionic acid, acetyl-CoA, niacin, riboflavin, thiamine, ribose, electron transfer substances such as NADH and FADH2, and other plant extracts such as aloe, feverfew, oatmeal, and their derivatives and mixtures. The cosmetic active agent is generally present in an amount of about 0.001% to about 20%, for example about 0.005% to about 10%, such as about 0.01% to about 5%, by weight of the topical skin preparation of the present invention.
[0073] Examples of vitamins include, but are not limited to, vitamin A, vitamin B (e.g., vitamin B3, vitamin B5, and vitamin B12), vitamin C, vitamin K, and different forms of vitamin E (e.g., α, β, γ, or Δ tocopherol) or mixtures thereof and derivatives thereof.
[0074] Examples of hydroxy acids include, but are not limited to, glycolic acid, lactic acid, malic acid, salicylic acid, citric acid, and tartaric acid.
[0075] Examples of antioxidants include, but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine), lipoic acid and dihydrolipoic acid, resveratrol, lactoferrin and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbic acid polypeptide). Oil-soluble antioxidants suitable for use in the skin topical preparations of the present invention include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol ethyl ester), tocotrienols and ubiquinone. Natural extracts containing antioxidants suitable for use in the skin topical preparations of the present invention include, but are not limited to, extracts containing flavonoids and isoflavones and their derivatives (e.g., genistein and di-zein), extracts containing resveratrol, and the like. Examples of such natural extracts include grape seeds, green tea, pine bark, and propolis.
[0076] How to use
[0077] The skin topical of the present invention can be topically applied to mammalian skin in need of treating one or more signs of skin aging as described above. In one embodiment, the skin topical can be applied to skin in need of treating fine lines and wrinkles and / or loss of elasticity. The skin topical can be applied to skin in need of such treatment according to a suitable treatment regimen, such as monthly, weekly, every other day, daily, twice a day, etc.
[0078] In certain embodiments, the skin topical preparations of the present invention can also be used to treat other needs related to the skin. For example, the skin topical preparations of the present invention can be used to treat hyperpigmentation after inflammation, to reduce pore size, to reduce sebum production, and to alleviate scars. In certain other embodiments, the skin topical preparations of the present invention can be applied simultaneously with a mechanical or physical epidermal exfoliation treatment (e.g., microdermabrasion treatment) or within a few hours of the treatment, or simultaneously with a chemical peel or keratolytic agent such as salicylic acid. In certain other embodiments, the skin topical preparations of the present invention can be applied to mucous membranes or other tissues such as vaginal tissue, oral tissue, or eye tissue. In certain other embodiments, the skin topical preparations of the present invention can be applied to mild wounds or postoperative sites to promote healing, to insect bites, to poison ivy skin disorders or similar skin conditions, or generally used to relieve itching.
[0079] The present invention is further described below in conjunction with specific examples. It is necessary to point out that the examples are only used to further illustrate the present invention and cannot be construed as limiting the scope of the present invention. Those skilled in the art can make some non-essential improvements and adjustments based on the content of the present invention described above. The test methods in the following examples that do not specify specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, all percentages and parts are by weight.
[0080] The stigmasterane mixture used in the present invention (a mixture of stigmasterane-22-ene-3,6-dione and 5α-stigmasterane-3,6-dione in a ratio of about 1:1) has a purity of more than 90%, is derived from chamomile, and is provided by the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences.
[0081] Example 1: Sample preparation
[0082] Weigh 42.77 mg of the stigmasterane mixture, dissolve it with dimethyl sulfoxide (Sigma, DMSO), add an appropriate amount of DMSO and make up to 100 mL volumetric flask to obtain a 427.7 mg / L stigmasterane mixture solution for use.
[0083] Example 2: Sample preparation
[0084] In a biosafety cabinet, 30 μL of Example 1 was pipetted with a pipette, and an appropriate amount of cell culture medium (DMEM culture medium, Guangdong Boxi Biotechnology Co., Ltd.) was added to 100 mL to obtain a 128.31 μg / L stigmasterane mixture solution for use.
[0085] Example 3: Sample preparation
[0086] In a biosafety cabinet, 15 μL of Example 1 was pipetted with a pipette, and an appropriate amount of cell culture medium (DMEM culture medium, Guangdong Boxi Biotechnology Co., Ltd.) was added to 100 mL to obtain a 64.16 μg / L stigmasterane mixture solution for use.
[0087] Test Example 1: Fibroblast Cytotoxicity Test
[0088] Cell inoculation: Skin fibroblasts (Guangdong Boxi Biotechnology Co., Ltd., Fb20081902) were plated at 8×10 3 The cells were seeded into a 96-well plate at a seeding density of 100 cells / well and incubated overnight in an incubator (Thermo, 150I) (37°C, 5% CO2).
[0089] Experimental grouping: The experiment set up a zero adjustment group, a solvent control group and a drug administration group. Example 1 set up 8 concentration gradients, and set up 3 replicate wells under each concentration gradient.
[0090] Solution preparation: Prepare the solution according to the table below.
[0091] Table 1
[0092]
[0093] Administration: Administration was performed when the cell plating rate in the 96-well plate reached 40% to 60%. 200 μL of DMEM culture medium (Guangdong Boxi Biotechnology Co., Ltd.) was added to each well of the solvent control group; 200 μL of culture medium containing a mixture of stigmasteranes of corresponding concentrations was added to each well of the drug administration group; the zero adjustment group had no cell inoculation and only 200 μL of cell culture medium was added. After administration, the 96-well plate was placed in an incubator for 24 hours.
[0094] Detection: After the cells were incubated for 24 hours, 20 μL of MTT (Sigma, 5 mg / mL) was added to each well and incubated at 37°C in the dark for 4 hours. After the incubation, the supernatant was discarded and 150 μL of DMSO was added to each well. The OD value was read at 490 nm and the cell survival rate was calculated. The results were expressed as Mean±SD.
[0095] Toxicity judgment method: The OD value of the sample group after MTT detection is compared with the OD value of the control group. After the turning point is screened out, 2 concentrations above and below the turning point are selected for morphological photography to verify the MTT result.
[0096]
[0097] Experimental results:
[0098] Table 2
[0099]
[0100] According to the MTT and morphological results (Table 2 and Figure 1-6 ) It can be seen that: Figure 2 The fibroblasts showed slight shrinkage in morphology, with a significant decrease in cell density and cytoplasmic transparency; Figure 3 The fibroblasts had clear edges and acceptable morphology, but the cell density was slightly reduced. Figure 2-3 and Figure 1 The difference is obvious. Figure 4-6 Fibroblasts have clear edges, stretched morphology, high cell density, homogeneous and transparent cells. Figure 1 (Solvent control group) had no significant difference. It showed that the stigmasterane mixture did not show obvious cytotoxicity based on fibroblasts within a mass concentration of 0.13 mg / L.
[0101] Test Example 2: Collagen I content test based on fibroblasts
[0102] Cell seeding: 4×10 4The cells were seeded into a 24-well plate at a seeding density of 100 cells / well and incubated overnight in an incubator (37° C., 5% CO 2 ).
[0103] Liquid preparation: divided into a blank control group, a model group (irradiated with UVA, the rest is the same as the blank group) and Example 1 group (128.31 μg / L and 64.16 μg / L).
[0104] Dosing: Dosing is performed when the cell plating rate in the 24-well plate reaches 40% to 60%. 2 mL of sample is added to each well, and 3 replicate wells are set up for each group. After dosing, the 24-well plate is placed in an incubator for 24 hours.
[0105] UVA irradiation: 30J / cm for the group that needs UVA irradiation 2 The cells were then placed in an incubator and exposed to UVA for 24 hours.
[0106] Sample collection: After 24 hours, collect the cell culture supernatant into an EP tube and store it in a -80°C refrigerator.
[0107] ELISA detection: The detection was performed according to the instruction manual of Collagen I ELISA kit (Human Collagen Type I (Col-I), Abcam). The results of Collagen I content were expressed as Mean ± SD.
[0108] Type I collagen (Collagen I) test results:
[0109] Table 3
[0110]
[0111] Compared with the blank control group, the content of Collagen I in the model group decreased from 26.99 ng / mL to 22.13 ng / mL, indicating that the stimulation conditions of this test were effective.
[0112] Compared with the model group, the content of Collagen I increased from 22.13ng / mL to 28.61ng / mL when the mass concentration of the stigmasterane mixture was 128.31μg / L, and increased from 22.13ng / mL to 25.21ng / mL when the mass concentration was 64.16μg / L. This indicates that the stigmasterane mixture can well promote the production of Collagen I by fibroblasts and achieve anti-wrinkle effect.
[0113] The stigmasterane mixture can be used for the preparation of medicines, health foods or skin external preparations. The skin external preparation is preferably a cosmetic composition, including but not limited to products in dosage forms such as creams, emulsions, gels, lotions, essences, facial masks, eye creams, aerosols (cleansing bubbles), sprays, shower gels and facial cleansers. The content of the stigmasterane mixture in the medicines, health foods or skin external preparations can be 0.000005-20% by weight, preferably 0.00001-10% by weight, and more preferably 0.00001-5% by weight.
[0114] The following are examples of specific applications of stigmasterane mixtures in medicines, health foods or external skin preparations, and the formulations and preparation methods of these dosage forms. In the following tables, "-" means no addition.
[0115] Application Example 1: Preparation of facial cream
[0116]
[0117] Application Example 2: Preparation of Emulsion
[0118]
[0119]
[0120] Application Example 3: Preparation of Gel
[0121]
[0122]
[0123] Application Example 4: Preparation of lotion
[0124]
[0125] Application Example 5: Preparation of Essence
[0126]
[0127]
[0128] Application Example 6: Preparation of facial mask
[0129]
[0130] Application Example 7: Preparation of Eye Cream
[0131]
[0132] Application Example 8: Preparation of Aerosol (Cleaning Bubble)
[0133]
[0134]
[0135] Application Example 9: Preparation of Spray
[0136]
[0137] Application Example 10: Preparation of Shower Gel
[0138]
[0139]
[0140] Application Example 11: Preparation of facial cleanser
[0141]
Claims
1. Application of stigmasterane mixture to promote collagen production.
2. The use according to claim 1, characterized in that The collagen is type I collagen.
3. The use according to claim 1, wherein: The stigmasterane mixture is used at a concentration of at least 0.05 mg / L.
4. The use according to claim 3, wherein: The stigmasterane mixture is used at a concentration of at least 0.1 mg / L.
5. Application of the stigmasterane mixture in the preparation of external skin preparations, medicines and health foods that promote collagen production.
6. The use according to claim 5, wherein: The collagen is type I collagen.
7. The use according to claim 5, wherein: The content of the stigmasterane mixture in external skin preparations, medicines and health foods is 0.000005-10% by weight.
8. The use according to claim 5, wherein: The content of the stigmasterane mixture in external skin preparations, medicines and health foods is 0.00001-5% by weight.
9. The use according to claim 5, wherein: The skin external preparation is selected from: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser.
